|
1
|
Singh S, Singh PP, Roberts LR and Sanchez
W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol. 11:45–54. 2014. View Article : Google Scholar
|
|
2
|
Motola-Kuba D, Zamora-Valdés D, Uribe M
and Méndez-Sánchez N: Hepatocellular carcinoma. An overview. Ann
Hepatol. 5:16–24. 2006.PubMed/NCBI
|
|
3
|
Li Y, Tang ZY and Hou JX: Hepatocellular
carcinoma: Insight from animal models. Nat Rev Gastroenterol
Hepatol. 9:32–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM,
Tang ZY, Sun Z, Harris CC and Thorgeirsson SS: Association of TP53
mutations with stem cell-like gene expression and survival of
patients with hepatocellular carcinoma. Gastroenterology.
140:1063–1070. 2011. View Article : Google Scholar :
|
|
5
|
Oishi N and Wang XW: Novel therapeutic
strategies for targeting liver cancer stem cells. Int J Biol Sci.
7:517–535. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma S, Tang KH, Chan YP, Lee TK, Kwan PS,
Castilho A, Ng I, Man K, Wong N, To KF, et al: miR-130b Promotes
CD133(+) liver tumor-initiating cell growth and self-renewal via
tumor protein 53-induced nuclear protein 1. Cell Stem Cell.
7:694–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tong CM, Ma S and Guan XY: Biology of
hepatic cancer stem cells. J Gastroenterol Hepatol. 26:1229–1237.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Penton AL, Leonard LD and Spinner NB:
Notch signaling in human development and disease. Semin Cell Dev
Biol. 23:450–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gray GE, Mann RS, Mitsiadis E, Henrique D,
Carcangiu ML, Banks A, Leiman J, Ward D, Ish-Horowitz D and
Artavanis-Tsakonas S: Human ligands of the Notch receptor. Am J
Pathol. 154:785–794. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoneya T, Tahara T, Nagao K, Yamada Y,
Yamamoto T, Osawa M, Miyatani S and Nishikawa M: Molecular cloning
of delta-4, a new mouse and human Notch ligand. J Biochem.
129:27–34. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Galic V, Shawber CJ, Reeves C, Shah M,
Murtomaki A, Wright J, Herzog T, Tong GX and Kitajewski J: NOTCH2
expression is decreased in epithelial ovarian cancer and is related
to the tumor histological subtype. Pathol Discov. 1:42013.
View Article : Google Scholar
|
|
12
|
Sehrawat A, Sakao K and Singh SV: Notch2
activation is protective against anticancer effects of zerumbone in
human breast cancer cells. Breast Cancer Res Treat. 146:543–555.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mazur PK, Einwächter H, Lee M, Sipos B,
Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G,
et al: Notch2 is required for progression of pancreatic
intraepithelial neoplasia and development of pancreatic ductal
adenocarcinoma. Proc Natl Acad Sci USA. 107:13438–13443. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang WJ, Yao Y, Jiang LL, Hu TH, Ma JQ,
Ruan ZP, Tian T, Guo H, Wang SH and Nan KJ: Increased LEF1
expression and decreased Notch2 expression are strong predictors of
poor outcomes in colorectal cancer patients. Dis Markers.
35:395–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu S, Zhang R, Liu F, Wang H, Wu J and
Wang Y: Notch inhibition suppresses nasopharyngeal carcinoma by
depleting cancer stem-like side population cells. Oncol Rep.
28:561–566. 2012.PubMed/NCBI
|
|
16
|
Sparks EE, Huppert KA, Brown MA,
Washington MK and Huppert SS: Notch signaling regulates formation
of the three-dimensional architecture of intrahepatic bile ducts in
mice. Hepatology. 51:1391–1400. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Geisler F, Nagl F, Mazur PK, Lee M,
Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM and Siveke JT:
Liver-specific inactivation of Notch2, but not Notch1, compromises
intrahepatic bile duct development in mice. Hepatology. 48:607–616.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao J, Song Z, Chen Y, Xia L, Wang J, Fan
R, Du R, Zhang F, Hong L, Song J, et al: Deregulated expression of
Notch receptors in human hepatocellular carcinoma. Dig Liver Dis.
40:114–121. 2008. View Article : Google Scholar
|
|
19
|
Dill MT, Tornillo L, Fritzius T,
Terracciano L, Semela D, Bettler B, Heim MH and Tchorz JS:
Constitutive Notch2 signaling induces hepatic tumors in mice.
Hepatology. 57:1607–1619. 2013. View Article : Google Scholar
|
|
20
|
Jeliazkova P, Jörs S, Lee M, Zimber-Strobl
U, Ferrer J, Schmid RM, Siveke JT and Geisler F: Canonical Notch2
signaling determines biliary cell fates of embryonic hepatoblasts
and adult hepatocytes independent of Hes1. Hepatology.
57:2469–2479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kamath BM, Bauer RC, Loomes KM, Chao G,
Gerfen J, Hutchinson A, Hardikar W, Hirschfield G, Jara P, Krantz
ID, et al: NOTCH2 mutations in Alagille syndrome. J Med Genet.
49:138–144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCright B, Lozier J and Gridley T: A
mouse model of Alagille syndrome: Notch2 as a genetic modifier of
Jag1 haploinsufficiency. Development. 129:1075–1082.
2002.PubMed/NCBI
|
|
23
|
Tchorz JS, Kinter J, Müller M, Tornillo L,
Heim MH and Bettler B: Notch2 signaling promotes biliary epithelial
cell fate specification and tubulogenesis during bile duct
development in mice. Hepatology. 50:871–879. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yen WC, Fischer MM, Axelrod F, Bond C,
Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, et al:
Targeting notch signaling with a notch2/notch3 antagonist
(tarextumab) inhibits tumor growth and decreases tumor-initiating
cell frequency. Clin Cancer Res. 21:2084–2095. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giovannini C, Gramantieri L, Chieco P,
Minguzzi M, Lago F, Pianetti S, Ramazzotti E, Marcu KB and Bolondi
L: Selective ablation of Notch3 in HCC enhances doxorubicin's death
promoting effect by a p53 dependent mechanism. J Hepatol.
50:969–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Litten JB, Chen TT, Schultz R, Herman K,
Comstock J, Schiffman J, Tomlinson GE and Rakheja D: Activated
NOTCH2 is overexpressed in hepatoblastomas: an immunohistochemical
study. Pediatr Dev Pathol. 14:378–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou BB, Zhang H, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug Discov.
8:806–823. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sukowati CH, Anfuso B, Torre G,
Francalanci P, Crocè LS and Tiribelli C: The expression of
CD90/Thy-1 in hepatocellular carcinoma: An in vivo and in vitro
study. PLoS One. 8:e768302013. View Article : Google Scholar : PubMed/NCBI
|
